Series A momentum InterVene recently closed a $13M Series A financing in October 2024 and added a new board member, signaling a fast-growing clinical-stage device company with heightened investor and governance support, presenting a timely opportunity for strategic partnerships, distribution agreements, or potential co-development discussions.

Clinical focus The flagship Recana Thrombectomy Catheter System targets venous in-stent restenosis and residual thrombotic obstructions, aligning with a specialty vascular interventional portfolio that can complement hospital inventory and provide sales touchpoints with vascular laboratories, endovascular centers, and CVIS teams.

Emerging markets With a small, specialized team and notable growth in financing history, InterVene is positioned to expand its clinical pipeline and geographic reach; partners in regional distributors and academic medical centers could accelerate adoption of Recana and future BlueLeaf-related technologies.

Strategic collaborations Past collaboration with Clinical Accelerator on early feasibility studies indicates openness to partnerships; sales opportunities may include research collaborations, feasibility trials, and joint development ventures with hospitals, research institutes, or device manufacturers.

Funding runway Overall funding of 34M and current revenue trajectory suggest a window for multi-year procurement planning, pricing discussions, and long-term value-based deals with healthcare systems looking to adopt innovative venous disease solutions and optimize patient outcomes.